HRP20181462T1 - Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva - Google Patents

Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Info

Publication number
HRP20181462T1
HRP20181462T1 HRP20181462TT HRP20181462T HRP20181462T1 HR P20181462 T1 HRP20181462 T1 HR P20181462T1 HR P20181462T T HRP20181462T T HR P20181462TT HR P20181462 T HRP20181462 T HR P20181462T HR P20181462 T1 HRP20181462 T1 HR P20181462T1
Authority
HR
Croatia
Prior art keywords
regorafenib
treatment
combination
colon cancer
acetylsalicylic acid
Prior art date
Application number
HRP20181462TT
Other languages
English (en)
Croatian (hr)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181462(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Ag filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20181462T1 publication Critical patent/HRP20181462T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181462TT 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva HRP20181462T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer
EP13770659.4A EP2900269B1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer

Publications (1)

Publication Number Publication Date
HRP20181462T1 true HRP20181462T1 (hr) 2018-11-02

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181462TT HRP20181462T1 (hr) 2012-09-25 2013-09-23 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Country Status (29)

Country Link
US (1) US10898500B2 (OSRAM)
EP (1) EP2900269B1 (OSRAM)
JP (1) JP6294888B2 (OSRAM)
KR (1) KR102210575B1 (OSRAM)
CN (1) CN104994876A (OSRAM)
AU (1) AU2013322854B2 (OSRAM)
BR (1) BR112015006686B1 (OSRAM)
CA (1) CA2885688C (OSRAM)
CL (1) CL2015000744A1 (OSRAM)
CY (1) CY1120939T1 (OSRAM)
DK (1) DK2900269T3 (OSRAM)
EA (1) EA032023B1 (OSRAM)
ES (1) ES2687985T3 (OSRAM)
HK (1) HK1214169A1 (OSRAM)
HR (1) HRP20181462T1 (OSRAM)
HU (1) HUE039878T2 (OSRAM)
IL (1) IL237690B (OSRAM)
LT (1) LT2900269T (OSRAM)
MX (1) MX357035B (OSRAM)
MY (1) MY183969A (OSRAM)
NZ (1) NZ705860A (OSRAM)
PH (1) PH12015500587A1 (OSRAM)
PL (1) PL2900269T3 (OSRAM)
PT (1) PT2900269T (OSRAM)
RS (1) RS57875B1 (OSRAM)
SG (2) SG10201702356VA (OSRAM)
SI (1) SI2900269T1 (OSRAM)
WO (1) WO2014048881A1 (OSRAM)
ZA (1) ZA201502840B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (OSRAM) 2012-06-13 2015-07-17 Hoffmann La Roche
MA37940B1 (fr) 2012-09-25 2018-09-28 Hoffmann La Roche Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EP3590939A1 (en) 2014-03-26 2020-01-08 F. Hoffmann-La Roche AG Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CA2984585A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
MX2018002217A (es) 2015-09-24 2018-03-23 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de autotaxina (atx).
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
EP3474858B1 (en) * 2016-06-28 2021-08-18 Asamedic AS Two-component composition comprising acetylsalicylic acid
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
WO2018219807A1 (en) * 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002014A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
NZ544920A (en) * 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR20080074974A (ko) * 2005-11-10 2008-08-13 바이엘 헬스케어 아게 당뇨병성 신경병증을 치료하기 위한 디아릴 우레아
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
HUE039878T2 (hu) 2019-02-28
US20150202214A1 (en) 2015-07-23
WO2014048881A1 (en) 2014-04-03
NZ705860A (en) 2018-07-27
SG11201501963RA (en) 2015-04-29
MX357035B (es) 2018-06-25
CY1120939T1 (el) 2019-12-11
EP2900269A1 (en) 2015-08-05
ES2687985T3 (es) 2018-10-30
AU2013322854A1 (en) 2015-04-02
IL237690B (en) 2019-07-31
CN104994876A (zh) 2015-10-21
US10898500B2 (en) 2021-01-26
SI2900269T1 (sl) 2018-10-30
MX2015003728A (es) 2015-09-23
EA032023B1 (ru) 2019-03-29
JP6294888B2 (ja) 2018-03-14
DK2900269T3 (en) 2018-10-01
IL237690A0 (en) 2015-05-31
LT2900269T (lt) 2018-11-12
CA2885688A1 (en) 2014-04-03
AU2013322854B2 (en) 2018-07-19
BR112015006686A2 (pt) 2019-08-27
MY183969A (en) 2021-03-17
KR20150060869A (ko) 2015-06-03
RS57875B1 (sr) 2018-12-31
HK1214169A1 (zh) 2016-07-22
KR102210575B1 (ko) 2021-02-02
SG10201702356VA (en) 2017-04-27
EA201500365A1 (ru) 2015-08-31
PT2900269T (pt) 2018-10-22
ZA201502840B (en) 2017-11-29
PH12015500587A1 (en) 2015-05-11
BR112015006686B1 (pt) 2022-04-05
PL2900269T3 (pl) 2019-02-28
CA2885688C (en) 2021-03-02
JP2015529234A (ja) 2015-10-05
EP2900269B1 (en) 2018-08-01
CL2015000744A1 (es) 2016-01-08

Similar Documents

Publication Publication Date Title
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
IL289300A (en) Combination therapy for treating cancer
IL282953A (en) Agents for treatment of claudin expressing cancer diseases
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
HUE036583T2 (hu) Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
PT2768493T (pt) Fitocanabinoides para utilização no tratamento do cancro da mama
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HUE046667T2 (hu) Rák kombinatív kezelése
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP3967315C0 (en) AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF CANCER
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
HUE045445T2 (hu) Kombinált terápia petefészekrák kezelésére
IL234606B (en) Novel methods and composition for treatment of disease
DK3434276T3 (da) Fremgangsmåde og farmaceutisk sammensætning til anvendelse i behandlingen af kræft
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro